Plus Therapeutics ((PSTV)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Plus Therapeutics is advancing a pivotal study titled ‘Safety and Efficacy of Autologous Adipose-Derived Regenerative Cells (ADRCs) Injection for Improving Diminished Ovarian Reserve (ARISE)’. This study aims to assess the safety and efficacy of ADRCs injections in enhancing ovarian function in women with Diminished Ovarian Reserve (DOR), a condition that significantly impacts fertility. The study’s significance lies in its potential to offer a novel regenerative therapy for DOR, addressing a critical gap in current fertility treatments.
The intervention being tested involves the intraovarian injection of Autologous Adipose-Derived Regenerative Cells (ADRCs). These cells are harvested from the patient’s adipose tissue and processed using the Celution® system. The primary purpose of this treatment is to improve ovarian function and fertility outcomes in women with DOR.
This interventional study is designed as a single-arm, self-controlled trial with no masking. It focuses on treatment as its primary purpose. Participants will receive the ADRCs injection, and their progress will be monitored over a 12-month period to evaluate changes in ovarian reserve markers and pregnancy rates.
The study is set to begin on August 5, 2025, with the primary completion date yet to be determined. The last update was also submitted on August 5, 2025. These dates are crucial for tracking the study’s progress and anticipating when results might become available.
For investors, this study update could influence Plus Therapeutics’ stock performance positively, as it highlights the company’s commitment to innovative treatments in the fertility space. The potential success of this study could set Plus Therapeutics apart from competitors and enhance investor confidence in its research capabilities.
The ARISE study is ongoing, with further details accessible on the ClinicalTrials portal.